Justification for the use of statins in primary prevention: An intervention trial evaluating rosuvastatin (JUPITER) - Can C-reactive protein be used to target statin therapy in primary prevention?

American Journal of Cardiology

Volumn 97, Issue 2 SUPPL. 1, 2006, Pages 33-41

  Mora, Samia ^a   Ridker, Paul M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID A PROTEIN; APOLIPOPROTEIN B; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; ROSUVASTATIN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; FOLLOW UP; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; KAPLAN MEIER METHOD; METABOLIC SYNDROME X; PRIORITY JOURNAL; REVIEW;

EID: 31344443020     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2005.11.014     Document Type: Article

References (34)

1. P. Libby, P.M. Ridker, A. Maseri Inflammation and atherosclerosis Circulation 105 2002 1135 1143
2. S.S. Bassuk, N. Rifai, P.M. Ridker High-sensitivity C-reactive protein clinical importance Curr Probl Cardiol 29 2004 439 493
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
4. P.W. Wilson, R.B. D'Agostino, D. Levy, A.M. Belanger, H. Silbershatz, W.B. Kannel Prediction of coronary heart disease using risk factor categories Circulation 97 1998 1837 1847
5. R.M. Conroy, K. Pyorala, A.P. Fitzgerald, S. Sans, A. Menotti, G. De Backer, D. De Bacquer, P. Ducimetiere, P. Jousilahti, U. Keil Estimation of ten-year risk of fatal cardiovascular disease in Europe the SCORE project Eur Heart J 24 2003 987 1003
6. E.S. Ford, W.H. Giles, A.H. Mokdad The distribution of 10-year risk for coronary heart disease among US adults findings from the National Health and Nutrition Examination Survey III J Am Coll Cardiol 43 2004 1791 1796
7. D.M. Lloyd-Jones, P.W. Wilson, M.G. Larson, A. Beiser, E.P. Leip, R.B. D'Agostino, D. Levy Framingham risk score and prediction of lifetime risk for coronary heart disease Am J Cardiol 94 2004 20 24
8. T.A. Pearson, G.A. Mensah, R.W. Alexander, J.L. Anderson, R.O. Cannon III, M. Criqui, Y.Y. Fadl, S.P. Fortmann, Y. Hong, G.L. Myers Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association Circulation 107 2003 499 511
9. P.M. Ridker, N. Rifai, M.A. Pfeffer, F. Sacks, E. Braunwald Cholesterol and Recurrent Events (CARE) Investigators Long-term effects of pravastatin on plasma concentration of C-reactive protein Circulation 100 1999 230 235
10. M.A. Albert, E. Danielson, N. Rifai, P.M. Ridker Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study JAMA 286 2001 64 70
11. L.H. Kuller, R.P. Tracy, J. Shaten, E.N. Meilahn Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study Multiple Risk Factor Intervention Trial Am J Epidemiol 144 1996 537 547
12. P.M. Ridker, M. Cushman, M.J. Stampfer, R.P. Tracy, C.H. Hennekens Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men N Engl J Med 336 1997 973 979
13. W. Koenig, M. Sund, M. Frohlich, H.G. Fischer, H. Lowel, A. Doring, W.L. Hutchinson, M.B. Pepys C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992 Circulation 99 1999 237 242
14. P.M. Ridker, C.H. Hennekens, J.E. Buring, N. Rifai C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women N Engl J Med 342 2000 836 843
15. P.M. Ridker, N. Rifai, L. Rose, J.E. Buring, N.R. Cook Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events N Engl J Med 347 2002 1557 1565
16. P.M. Ridker, J.E. Buring, N.R. Cook, N. Rifai C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events an 8-year follow-up of 14 719 initially healthy American women Circulation 107 2003 391 397
17. P.M. Ridker, M.J. Stampfer, N. Rifai Novel risk factors for systemic atherosclerosis a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease JAMA 285 2001 2481 2485
18. A.D. Pradhan, J.E. Manson, N. Rifai, J.E. Buring, P.M. Ridker C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus JAMA 286 2001 327 334
19. W. Koenig, H. Lowel, J. Baumert, C. Meisinger C-reactive protein modulates risk prediction based on the Framingham score: implications for future risk assessment: results from a large cohort study in southern Germany Circulation 109 2004 1349 1353
20. C.M. Ballantyne, R.C. Hoogeveen, H. Bang, J. Coresh, A.R. Folsom, G. Heiss, A.R. Sharrett Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study Circulation 109 2004 837 842
21. J. Danesh, J.G. Wheeler, G.M. Hirschfield, S. Eda, G. Eiriksdottir, A. Rumley, G.D. Lowe, M.B. Pepys, V. Gudnason C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease N Engl J Med 350 2004 1387 1397
22. J.K. Pai, T. Pischon, J. Ma, J.E. Manson, S.E. Hankinson, K. Joshipura, G.C. Curhan, N. Rifai, C.C. Cannuscio, M.J. Stampfer, E.B. Rimm Inflammatory markers and the risk of coronary heart disease in men and women N Engl J Med 351 2004 2599 2610
23. S.C. Smith Jr, J.L. Anderson, R.O. Cannon III, Y.Y. Fadl, W. Koenig, P. Libby, S.E. Lipshultz, G.A. Mensah, P.M. Ridker, R. Rosenson CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the clinical practice discussion group Circulation 110 2004 e550 e553
24. V. Pasceri, J.T. Willerson, E.T. Yeh Direct proinflammatory effect of C-reactive protein on human endothelial cells Circulation 102 2000 2165 2168
25. T.P. Zwaka, V. Hombach, J. Torzewski C-reactive protein-mediated low density lipoprotein uptake by macrophages implications for atherosclerosis Circulation 103 2001 1194 1197
26. S. Verma, C.H. Wang, S.H. Li, A.S. Dumont, P.W. Fedak, M.V. Badiwala, B. Dhillon, R.D. Weisel, R.K. Li, D.A. Mickle, D.J. Stewart A self-fulfilling prophecy C-reactive protein attenuates nitric oxide production and inhibits angiogenesis Circulation 106 2002 913 919
27. S. Devaraj, D.Y. Xu, I. Jialal C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells implications for the metabolic syndrome and atherothrombosis Circulation 107 2003 398 404
28. P. Calabro, J.T. Willerson, E.T. Yeh Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells Circulation 108 2003 1930 1932
29. W.J. Jabs, E. Theissing, M. Nitschke, J.F. Bechtel, M. Duchrow, S. Mohamed, B. Jahrbeck, H.H. Sievers, J. Steinhoff, C. Bartels Local generation of C-reactive protein in diseased coronary artery venous bypass grafts and normal vascular tissue Circulation 108 2003 1428 1431
30. S.E. Nissen, E.M. Tuzcu, P. Schoenhagen, T. Crowe, W.J. Sasiela, J. Tsai, J. Orazem, R.D. Magorien, C. O'Shaughnessy, P. Ganz Statin therapy, LDL-C, C-reactive protein, and coronary artery disease N Engl J Med 352 2005 29 38
31. P.M. Ridker, C.P. Cannon, D. Morrow, N. Rifai, L.M. Rose, C.H. McCabe, M.A. Pfeffer, E. Braunwald C-reactive protein levels and outcomes after statin therapy N Engl J Med 352 2005 20 28
32. P.M. Ridker, N. Rifai, M.A. Pfeffer, F.M. Sacks, L.A. Moye, S. Goldman, G.C. Flaker, E. Braunwald Cholesterol and Recurrent Events (CARE) Investigators Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels Circulation 98 1998 839 844
33. P.M. Ridker, N. Rifai, M. Clearfield, J.R. Downs, S.E. Weis, J.S. Miles, A.M. Gotto Jr Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events N Engl J Med 344 2001 1959 1965
34. P.M. Ridker Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein rationale and design of the JUPITER trial Circulation 108 2003 2292 2297